 | Up a level |
Number of items: 1.
Waldschmidt, D., Teufel, M., Koechert, K., Meinhardt, G. and Bruix, J. (2018). Efficacy of regorafenib (REG) in patients with hepatocellular carcinoma (HCC) in the phase III RESORCE trial according to alpha-fetoprotein (AFP) and c-Met levels as predictors of poor prognosis. Oncol. Res. Treat., 41. S. 281 - 283. BASEL: KARGER. ISSN 2296-5262